# Filgrastim-Sndz (Zarxio)

Source: https://ourhealthnetwork.com/drugs/filgrastim-sndz
Data: FDA Orange Book and OpenFDA, refreshed periodically

## What is Filgrastim-Sndz?

Filgrastim-Sndz (brand name: Zarxio) is a leukocyte growth factor. It is prescribed to treat neutropenia. Across the United States, 450 doctors prescribe Filgrastim-Sndz to approximately 1,000 Medicare patients.

## Brand names

Zarxio

## Indications

Filgrastim-Sndz is primarily prescribed for the treatment of neutropenia.

## Conditions treated

- [Neutropenia](https://ourhealthnetwork.com/conditions/neutropenia)

## Mechanism of action

Colony-stimulating factors are glycoproteins which act on hematopoietic cells by binding to specific cell surface receptors and stimulating proliferation‚ differentiation commitment‚ and some end-cell functional activation. Endogenous G-CSF is a lineage-specific colony-stimulating factor that is produced by monocytes‚ fibroblasts, and endothelial cells.

## Drug classification

- Established Pharmacologic Class: Leukocyte Growth Factor [EPC]
- Route of administration: INTRAVENOUS

## Common side effects

adverse reactions in patients: • With nonmyeloid malignancies receiving myelosuppressive anti-cancer drugs (≥ 5% difference in incidence compared to placebo) are pyrexia, pain, rash, cough, and dyspnea

## Sources and disclaimers

- FDA Orange Book and OpenFDA dataset
- This information is for educational purposes only and does not constitute medical advice. Always consult a healthcare professional before starting, stopping, or changing any medication.

## Related

- [All drugs](https://ourhealthnetwork.com/drugs)
- [Find specialists who prescribe this drug](https://ourhealthnetwork.com/find-doctors)
- [Methodology](https://ourhealthnetwork.com/methodology)